Background
==========

Antineutrophil cytoplasmic antibodies (ANCA) are autoimmune antibodies against neutrophil cytoplasmic components, and has become a specific serological marker antibody for systemic vasculitis represented by Wegener's granulomatosis (WG) in recent years. ANCA, as an important serological diagnosis of vasculitis, is widely recognized by the medical profession for its usefulness in assessing the remission and recurrence status of diseases.

ANCA is divided into cANCA and pANCA, and the matrix tablets for detection of ANCA include ethanol-immobilized neutrophils, formalin-fixed neutrophils, HEP-2 cells, and monkey liver tissues, the latter 2 are mainly to exclude ANA interference in the detection. The main target antigen of pANCA is anti-myeloperoxidase (MPO). MPO is a highly cationic protein with a molecular weight of 146 000, which can cause continuous ribbon fluorescence in the periphery of neutrophils. The main target antigen of cANCA is anti-protease 3 (PR3), which can cause the whole cytoplasmic region of neutrophils to cover coarse particles.

Primary vasculitis is a not yet clear etiology of a class of small vasculitis, mainly violations of small blood vessels, such as small arteries, arteries, vascular wall necrosis inflammation, cellulose-like necrosis as a pathological feature, is a class of sexually transmitted autoimmune diseases. Primary vasculitis generally refers to microscopic multiple vasculitis (MPA), Wegener's granulomatosis (WG), Churg-Strauss syndrome (CSS), and primary necrosis crescentic glomerulonephritis (NCGN). Clinically, WG, MPA, CSS, NCGN, and other series of diseases are called ANCA-related systemic vasculitis (AASV). AASV is a kind of small vascular wall inflammation and/or fibrinoid necrosis, and is the pathological basis of a group of autoimmune diseases, mainly involving systemic small vessel autoimmune disease, and is the most common adult primary vasculitis. ANCA and its target antigen are widely used in clinical practice, and the incidence of AASV is increasing. In this paper, the results of ANCA testing in 118 730 cases in tertiary care hospitals in Jiangxi Province, China, from January 2014 to December 2016 were retrospectively analyzed.

Material and Methods
====================

Review of the cases
-------------------

Retrospective statistical analysis was completed in tertiary (3A) hospitals of Jiangxi Province from January 2014 to December 2016. Of the total of 118 730 cases with ANCA test results, there were 23 720 cases from the Second Affiliated Hospital of Nanchang University, 33 770 cases from the First Affiliated Hospital of Nanchang University, 18 cases from Jiangxi Provincial People's Hospital, 1630 cases from Jiangxi Provincial Hospital of Traditional Chinese Medicine, 3890 cases from the Fourth Affiliated Hospital of Nanchang University, 6510 cases from the Affiliated Hospital of Jiujiang University, 8480 cases from Yichun People's Hospital of Jiangxi Province, 10 070 cases from the Affiliated Hospital of Gannan Medical University, 7580 cases from Ganzhou People's Hospital of Jiangxi Province, and 5060 cases from Pingxiang People's Hospital of Jiangxi Province. There were 41 633 men and 77 097 women in total and the ratio of males to females was 1: 1.85. Ages ranged from 1 to 109 years old, with an average of 51.5±12.1 years. Positive results appeared in 5853 cases, in which 2053 were vasculitis, including Wegener's granuloma (696 cases), microvascular polyvascular (659 cases), eosinophilic granulomatous vasculitis (173 cases), nodular polyarteritis (251 cases), aorta arteritis (121 cases), IgA vasculitis (53 cases), and Behçet's disease (54 cases). Among the positive cases, 3612 had other autoimmune diseases, including 54 cases of autoimmune hepatitis, 115 cases of primary biliary cirrhosis, 98 cases of primary sclerosing cholangitis, 825 cases of rheumatoid arthritis, 1182 cases of systemic lupus erythematosus, 565 cases of ulcerative colitis, 404 cases of mixed connective tissue disease, 82 cases of scleroderma, 287 cases of Sjögren's syndrome, 75 cases of type 2 diabetes mellitus, and 188 cases of other types of diseases. We selected 100 healthy participants as the control group. Written informed consent was obtained from all subjects. The diagnosis of vasculitis was based on the diagnostic criteria of vasculitis \[[@b1-medscimonit-23-4312]\], and rheumatoid arthritis and systemic lupus erythematosus and other autoimmune diseases were diagnosed according to the standards established by the American Society of Rheumatology (ACR) \[[@b2-medscimonit-23-4312]\]. All specimens were obtained with the patient's informed consent and approved by the Hospital Ethics Committee.

Instruments and reagents
------------------------

Many types of fluorescence microscopes were used, including EUPOStar Plus, Nikon, and OLYMPUS BX. Microplate readers used included SUNRISE, ELX 808, and Multiscan MK3. Washing machines used included PW-960 automatic, ELX 50, and BioTek automatic. Reagents used were the antineutrophil cytoplasmic IgG test kit, Anti-MPO assay kit, and the anti-PR3 assay kit provided by EUROIMMUN (Germany).

Methods
-------

ANCA fluorescence pattern was determined by IIF method. Reagents were purchased from EUROIMMUN Company (Germany). The reaction areas included HEp-2 cells, primate liver tissue, and formaldehyde- and ethanol-fixed human neutrophils. Samples were diluted with PBST buffer for 1: 10 dilution and tested in strict accordance with the EUROIMMUN titration plate technique. The above steps were in strict accordance with the reagent manual and the standard operating procedure (SOP) in our laboratory.

Human serum anti-MPO and anti-PR3 antibodies were tested by enzyme-linked immunosorbent assay (ELISA) method. Reagents were from EUROIMMUN Company. The samples were diluted, then the diluted sera, negative control, positive control, and blank control were added to the microwells. The platelets were incubated for 30 min at room temperature. After incubation, plates were washed. Human IgG bound on the plates was detected by horseradish peroxidase-conjugated antibody using tetramethylbenzidine (TMB) as a peroxidase substrate. The reaction was stopped by the addition of 2 M H~2~SO~4~, and the absorbance was read at 450 nm. The above steps were in strict accordance with the reagent manual and the SOP.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS 19.0 (SPSS for Windows, ver. 19.0). Quantitative variables are presented as mean ±SD. The validity was checked using the rank sum test. The χ^2^ test was used to compare categorical variables. *P*\<0.05 was considered as statistical significance.

Results
=======

The analysis of total positive rate
-----------------------------------

Among 118 730 cases with ANCA test results, there were 5853 positive cases. There was a significant difference between the positive male and positive female groups (χ^2^=123.38, *P*\<0.01) ([Table 1](#t1-medscimonit-23-4312){ref-type="table"}).

The departmental distribution of the 5853 cases positive for ANCA
-----------------------------------------------------------------

The department with highest positive rate was the Department of Rheumatology, which was consistent with the specificity of ANCA-positive status in vasculitis patients treated in this department ([Table 2](#t2-medscimonit-23-4312){ref-type="table"}).

Test results of anti-PR3, anti-MPO, and ANCA antibody in 5853 positive cases
----------------------------------------------------------------------------

Anti-PR3 and cANCA pattern were highly specific in vasculitis. The anti-MPO and pANCA pattern had high specificity for other autoimmune disease ([Table 3](#t3-medscimonit-23-4312){ref-type="table"}).

Comparison of the concentration of anti-PR3 and anti-MPO antibody in autoimmune diseases
----------------------------------------------------------------------------------------

In the vasculitis group, the concentration and positive rate of anti-PR3 antibody was highest, and in other autoimmune diseases the concentration and positive rate of anti-MPO antibody was highest, as shown in [Table 4](#t4-medscimonit-23-4312){ref-type="table"}.

The positive rate in the different types of diseases positive for ANCA
----------------------------------------------------------------------

The positive rate of ANCA in vasculitis was higher than that in other autoimmune diseases. The positive rate of Wegener's granuloma was the highest in the vasculitis group (71.60%). The positive rate of systemic lupus erythematosus was the highest (6.13%) in the other autoimmune diseases group ([Table 5](#t5-medscimonit-23-4312){ref-type="table"}).

The positive rate of anti-PR3 and anti-MPO antibody and 2 patterns of ANCA in different diseases
------------------------------------------------------------------------------------------------

In the group with vasculitis, Wegener's granulomatosis had the highest positive rate of anti-PR3 (75.41%) and cANCA (67.96%). Microscopic vasculitis had the highest positive rate of anti-MPO antibodies (54.32%) and pANCA (57.51%). In the group of other autoimmune diseases, systemic lupus erythematosus (SLE) had the highest positive rate of anti-MPO (86.13%) and pANCA (87.73%). Data are shown in [Table 6](#t6-medscimonit-23-4312){ref-type="table"}.

Organ involvement accompanied by 2 patterns of ANCA antibody
------------------------------------------------------------

The positive rate of pANCA was higher than that of cANCA in cases of kidney involvement, liver involvement, ear involvement, nasal involvement, muscle involvement, nerve system involvement, and digestive tract involvement. The positive rate of cANCA was more than that of pANCA in cases of eye involvement and joint involvement. See details in [Table 7](#t7-medscimonit-23-4312){ref-type="table"}.

Clinical evaluation of anti-PR3, anti-MPO, cANCA, and pANCA
-----------------------------------------------------------

Anti-PR3 and cANCA were more sensitive and specific, as shown in [Table 8](#t8-medscimonit-23-4312){ref-type="table"}.

Discussion
==========

In 1982, Davies \[[@b4-medscimonit-23-4312]\] detected an IgG type of antibody in patients with segmental necrotizing glomerulonephritis in serum by the IIF method. The antibody antigen is neutrophil cytoplasmic antigen, so it is called ANCA. Later, Van der Woude \[[@b5-medscimonit-23-4312]\] confirmed the presence of ANCA in serum of patients with Wegener's granulomatosis and identified a specific serological diagnostic value. The important clinical role of ANCA was recognized.

We retrospectively analyzed the test results of 118 730 cases in tertiary hospitals for ANCA from January 2014 to December 2016 in Jiangxi Province. There were 5853 positive cases **(**4.93%), which is similar to rates in Chinese and foreign reports. For the positivity of ANCA, the male-to-female ratio was 1: 1.85, which is consistent with the literature \[[@b6-medscimonit-23-4312]--[@b11-medscimonit-23-4312]\].

The department with the highest positive rate (15.06%) of ANCA was the Department of Rheumatology in tertiary care hospitals in Jiangxi Province, which is consistent with the specificity of ANCA in rheumatism. The positive rate in dermatology was up to 7.78%, because a common complication of vasculitis is skin rash. The renal positive rate can be up to 6.79%, which is related to ANCA-associated vasculitis, mainly involved in kidney disease, such as rapid progressive glomerulonephritis and necrotic crescentic nephritis \[[@b12-medscimonit-23-4312]--[@b14-medscimonit-23-4312]\].

Among 2053 cases of vasculitis and 3612 cases of other autoimmune diseases, anti-PR3 and cANCA were highly specific in vasculitis. Anti-MPO and pANCA had high specificity for other autoimmune diseases, which is consistent with the literature \[[@b25-medscimonit-23-4312]--[@b31-medscimonit-23-4312]. There were 748 cases of vasculitis patients with anti-PR3 concentrations of 31.65±17.75 IU/ml, with significant differences compared with the other autoimmune diseases group. It may be concluded that anti-PR3 in vasculitis has a high degree of specificity. There were 457 cases of other autoimmune diseases with anti-MPO antibody concentration of 74.58±41.10 IU/ml, and there were significant differences from the vasculitis group. MPO antibody was highly specific in other autoimmune diseases. This result is consistent with previous studies \[[@b32-medscimonit-23-4312]--[@b41-medscimonit-23-4312]\].

Initially, it was found that ANCA existed in the sera of patients with primary vasculitis. As the study of ANCA became more comprehensive, and with the wider clinical use of ANCA, the value of ANCA in diagnosis and prognosis of diseases is increasingly recognized in the medical field. ANCA can be divided into cANCA and pANCA according to the different patterns of immunofluorescence. Some target antigens and some patterns of ANCA are recognized to have a close relationship with some diseases. In our study, anti-PR3 and cANCA were mainly seen in Wegener's granuloma, while anti-MPO and pANCA were mostly seen in microscopic multiple vasculitis. This result is slightly different from Martínez Téllez \[[@b42-medscimonit-23-4312]\] because the Chinese and Western ANCA-related target antigen corresponding to the disease is different. ANCA contains a variety of antigenic components: mainly anti-MPO and anti-PR3. Additionally, among 5853 patients positive for ANCA, we did not detect anti-MPO or anti-PR3 antibodies in 1034 patients, indicating that in addition to the 2 common target antigens, there were other antigens present, including lysozyme, cathepsin, elastase, and lactoferrin, which is consistent with the literature \[[@b43-medscimonit-23-4312]--[@b50-medscimonit-23-4312]\]. Further confirmation of other specific target antigens needs to be confirmed.

In 5853 cases with positive results for ANCA, 2053 cases were diagnosed with vasculitis. PR3-ANCA in Wegener's granuloma had a significant positive rate of 75.14%, while the positive rate of MPO-ANCA was 54.32% in microscopic multiple vasculitis. It was slight lower compared with the results from Zhang \[[@b51-medscimonit-23-4312]\], and there is a huge difference between the distribution of patients in different cities and using different detection methods. Eosinophilic granulomatous vasculitis in AAV is rare, and this might be related to the low incidence rate in China, and is in line with the literature \[[@b52-medscimonit-23-4312]--[@b59-medscimonit-23-4312]\]. In 3612 cases of other autoimmune diseases, clinical diseases were mainly SLE-based (20.19% positive) and RA-based (14.10% positive), and given priority to anti-MPO and pANCA. Ulcerative colitis is a type of autoimmune disease with a high positive rate. The anti-MPO and pANCA had a high specificity, which is basically consistent with previous reports \[[@b60-medscimonit-23-4312],[@b61-medscimonit-23-4312]\].

ANCA-associated vasculitis mainly involves the kidneys and liver. The positive rate can be up to 25.35% and 23.87%. In addition, the involvement of joints, muscles, nervous system, and digestive tract suggest multi-organ involvement. The positive rate of pANCA was higher than that of cANCA in cases involving the kidneys, liver, ears, nose, muscles, nerves, and digestive tract. The positive rate of cANCA was higher than that of pANCA in cases of eye involvement and joint involvement, consistent with the literature \[[@b62-medscimonit-23-4312],[@b63-medscimonit-23-4312]\]. Organ involvement with ANCA-associated vasculitis has a variety of clinical manifestations, resulting in different diseases. Hence, this characteristic causes various difficulties in clinical diagnosis, which need to be explored in greater detail.

There were some limitations to the present study. The first is the limitations of indirect immunofluorescence interpretation. According to the different staining sites of immunofluorescence, ANCA can be divided into cANCA and pANCA. Each hospital has subjective factors when reading data from the fluorescent microscope. The second is the limitations of the target antigen. The 2 major target antigens of ANCA are anti-MPO and anti-PR3 (as studied in this paper). However, there are many ANCA-associated target antigens, and the diseases associated with these target antigens in this study are included in the "other diseases" because of the small clinical base, which is not covered in this article and needs further studies. The last one is the limitations of the study object. The clinical data, which was collected from China, were slightly different from the foreign reports.

Conclusions
===========

ANCA enables early diagnosis and treatment of primary vasculitis. With the development of ANCA detection, and as detection technology improves, the detection rate of ANCA in diseases is increasing and more types of diseases can be detected through this method. Therefore, much more attention should be paid to ANCA in the diagnosis of clinical disease.
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###### 

ANCA test results.

              Number of cases   Number of positive cases   Positive rate (%)
  ----------- ----------------- -------------------------- -------------------
  Male        41633             1657                       3.98
  Female      77097             4196                       6.33
  **Total**   **118730**        **5853**                   **4.93**
  χ^2^                          123.38                     
  P                             \<0.01                     

The χ^2^ test was used, and the results showed that ANCA-positivity was associated with sex (χ^2^=123.38, *P*\<0.01)*.*

###### 

Departmental distribution with cases positive for ANCA.

  Department             Number checked   Positive number   Positive rate (%)   Department                          Number checked   Positive number   Positive rate (%)
  ---------------------- ---------------- ----------------- ------------------- ----------------------------------- ---------------- ----------------- -------------------
  Rheumatology           28894            4352              15.06               Department of Infectious Diseases   3720             134               3.60
  Nephrology             20350            1382              6.79                Pediatrics                          808              34                4.21
  Neurology              11210            255               1.79                Traditional Chinese Medicine        4723             270               5.72
  Gastroenterology       12100            471               3.89                Dermatology                         1207             94                7.78
  Hematology             10732            328               3.06                Geriatrics                          721              35                4.85
  Respiratory medicine   11906            576               4.84                General surgery                     140              20                1.43
  Painful disease        980              24                2.45                Outpatient                          10239            655               6.39

###### 

The results of anti-PR3, anti-MPO, and ANCA antibody in 5853 cases.

  Group                                Number of cases   Anti-PR3-positive                                         Anti-MPO-positive   ANCA-positive                                                                                                                                                                                   
  ------------------------------------ ----------------- --------------------------------------------------------- ------------------- ---------------------------------------------------------- ------- --------------------------------------------------------- ------- ---------------------------------------------------------- -------
  Vasculitis                           2053              748                                                       41.31               708                                                        29.61   667                                                       32.49   760                                                        37.02
  Other autoimmune diseases            3612              457[\#](#tfn3-medscimonit-23-4312){ref-type="table-fn"}   12.65               2140[\#](#tfn3-medscimonit-23-4312){ref-type="table-fn"}   59.25   329[\#](#tfn3-medscimonit-23-4312){ref-type="table-fn"}   9.11    2779[\#](#tfn3-medscimonit-23-4312){ref-type="table-fn"}   79.94
  Other                                188               45                                                        23.94               105                                                        55.85   50                                                        26.60   106                                                        56.38
  Healthy physical examination group   100               0[\*](#tfn2-medscimonit-23-4312){ref-type="table-fn"}     0.00                0[\*](#tfn2-medscimonit-23-4312){ref-type="table-fn"}      0.00    0[\*](#tfn2-medscimonit-23-4312){ref-type="table-fn"}     0.00    0[\*](#tfn2-medscimonit-23-4312){ref-type="table-fn"}      0.00
  Total                                5953              1295                                                      21.75               3062                                                       51.44   1096                                                      18.41   3751                                                       63.01

Compared with vasculitis and autoimmune diseases, by χ^2^ test, *P\<0.01*, the results had a very significant significance.

Compared with vasculitis, by χ^2^ test, *P\<0.01*, the results had a very significant significance.

###### 

MPO antibody and anti-PR3concentration test results.

  Group                       Number of cases   Anti-PR3-positive                                         Anti-MPO-positive                                                             
  --------------------------- ----------------- --------------------------------------------------------- ------------------- --------------------------------------------------------- -------------
  Vasculitis                  2053              748[\#](#tfn4-medscimonit-23-4312){ref-type="table-fn"}   31.65±17.75         708[\#](#tfn4-medscimonit-23-4312){ref-type="table-fn"}   47.23±21.58
  Other autoimmune diseases   3612              457                                                       18.22±10.91         2140                                                      74.58±41.10
  Other diseases              188               45                                                        6.28±3.39           105                                                       7.48± 7.86

Compared with other autoimmune diseases, the results were very significant (*P*\<0.01) in the rank sum test.

###### 

The 5853 cases with ANCA-confirmed clinical diagnosis and positive rate.

  Disease type                    Detection of total number of cases   Number of positive cases   Positive rate (%)
  ------------------------------- ------------------------------------ -------------------------- -------------------
  **Vasculitis**                                                                                  
   WG                             972                                  696                        71.60
   MPA                            983                                  659                        67.03
   CSS                            317                                  173                        54.57
   PAN                            572                                  251                        43.88
   TA                             298                                  121                        40.60
   IgAV                           251                                  99                         39.44
   BD                             220                                  54                         24.55
  **Other autoimmune diseases**                                                                   
   AIH                            7655                                 54                         0.71
   PBC                            6008                                 115                        1.91
   PSC                            7434                                 98                         1.32
   RA                             21773                                825                        3.79
   SLE                            19297                                1182                       6.13
   UC                             10450                                565                        5.41
   MCTD                           10358                                404                        3.90
   PSS                            7026                                 82                         1.17
   SS                             7572                                 287                        3.79
   T2DM                           12541                                75                         0.60
  **Other diseases**              5003                                 113                        2.25
  **Total**                       **118730**                           **5853**                   **4.93**

###### 

Positive rate of anti-MPO, anti-PR3 antibody, and 2 patterns of ANCA in different diseases.

  Disease types                   Number of cases   Anti-PR3-positive   Anti-MPO-positive   ANCA-positive                                
  ------------------------------- ----------------- ------------------- ------------------- --------------- ------- ----- ------- ------ -------
  **Vasculitis**                                                                                                                         
   WG                             696               523                 75.14               24              3.45    473   67.96   13     1.88
   MPA                            659               101                 15.33               358             54.32   84    12.75   379    57.51
   CSS                            173               18                  10.40               90              52.02   15    8.76    95     54.91
   PAN                            251               22                  8.76                125             49.80   22    8.76    142    56.57
   TA                             121               59                  48.76               35              28.92   44    36.36   49     40.49
   IgAV                           99                23                  23.23               42              44.44   25    25.25   46     46.46
   BD                             54                2                   3.70                22              40.74   4     7.41    26     48.15
  **Other autoimmune diseases**                                                                                                          
   AIH                            54                3                   5.56                27              50.00   5     9.26    33     6.11
   PBC                            115               12                  10.43               55              47.83   9     7.83    78     67.83
   PSC                            98                1                   1.02                52              53.06   0     0       56     57.14
   RA                             825               223                 27.03               251             30.42   119   14.42   704    85.33
   SLE                            1182              20                  1.69                1018            86.13   27    2.28    1037   87.73
   UC                             565               29                  5.13                361             63.89   22    3.89    454    80.35
   MCTD                           404               110                 27.23               141             34.90   112   27.72   169    41.83
   PSS                            82                5                   6.10                10              12.20   2     2.43    17     20.73
   SS                             287               54                  18.82               225             78.40   33    11.50   231    80.49
   T2DM                           75                17                  22.67               35              46.67   19    25.33   40     53.33
  **Other**                       113               28                  24.78               70              61.95   31    27.43   66     58.41

###### 

Organ involvement related with pANCA and cANCA.

  Type of involvement           Total number of cases   cANCA-positive (1046)                                     pANCA-positive (3645)   χ^2^           
  ----------------------------- ----------------------- --------------------------------------------------------- ----------------------- ------ ------- --------
  Kidney involvement            1484                    283[\#](#tfn6-medscimonit-23-4312){ref-type="table-fn"}   27.06                   1201   32.95   0.67
  Liver involvement             1397                    209[\#](#tfn6-medscimonit-23-4312){ref-type="table-fn"}   19.98                   1188   32.59   159.36
  Eye involvement               342                     121[\#](#tfn6-medscimonit-23-4312){ref-type="table-fn"}   11.57                   221    6.06    36.43
  Ear involvement               354                     65[\*](#tfn5-medscimonit-23-4312){ref-type="table-fn"}    6.21                    299    8.20    4.14
  Nasal involvement             279                     33[\#](#tfn6-medscimonit-23-4312){ref-type="table-fn"}    3.15                    215    5.90    8.12
  Joint involvement             544                     129[\*](#tfn5-medscimonit-23-4312){ref-type="table-fn"}   12.33                   415    11.39   5.78
  Muscle involvement            438                     71[\#](#tfn6-medscimonit-23-4312){ref-type="table-fn"}    6.79                    367    10.07   10.34
  Nervous system involvement    268                     44[\*](#tfn5-medscimonit-23-4312){ref-type="table-fn"}    4.21                    224    6.15    5.57
  Digestive tract involvement   741                     101[\#](#tfn6-medscimonit-23-4312){ref-type="table-fn"}   9.66                    640    17.56   38.16
  Other organs involved         69                      24[\*](#tfn5-medscimonit-23-4312){ref-type="table-fn"}    2.29                    45     1.23    6.30

Compared with pANCA, the results were significant by χ^2^ test (*P*\<0.05).

Compared with pANCA, the results are very significant by χ^2^ test (*P*\<0.01).

###### 

Clinical evaluation of anti-PR3, anti-MPO antibody, and ANCA results.

  Test items   Sensitivity (%)   Specificity (%)   Prevalence (%)   Positive predictive value (%)   Negative predictive value (%)   Positive likelihood ratio (%)   Negative likelihood ratio (%)
  ------------ ----------------- ----------------- ---------------- ------------------------------- ------------------------------- ------------------------------- -------------------------------
  Anti-PR3     62.02             70.74             21.27            36.43                           87.35                           2.12                            53.69
  Anti-MPO     24.86             52.25             50.27            34.49                           40.75                           0.52                            143.81
  cANCA        66.97             70.31             17.58            32.49                           90.89                           2.26                            46.98
  pANCA        21.47             39.18             62.27            37.02                           23.06                           0.35                            200.43
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